Abstract
The aim of the present study was to evaluate the osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B ligand (RANKL), oxidant, and antioxidant status in untreated active pulmonary tuberculosis patients (PTB). Serum was obtained from 42 patients with different forms of untreated active PTB and 41 healthy subjects, as the control group. The serum levels of OPG, RANKL, tumor necrosis factor alpha (TNFα), malondialdehyde (MDA), total antioxidant capacity (TAC), and the lipid profiles were determined using standard methods. Patients with PTB were detected to have significantly higher plasma MDA, TNFα, OPG, and RANKL levels, and lower TAC levels, when compared to the healthy controls(p < 0.05 in all of the cases). Low TAC and high MDA levels in PTB patients are indicators of oxidative stress in these patients. Severe oxidative stress and increased RANKL and OPG may induce vascular calcification in PTB patients.
Similar content being viewed by others
References
Rota S. Mycobacterium tuberculosis complex in atherosclerosis. Acta Med Okayama. 2005;59(6):247–51.
Sasindran SJ, Torrelles JB. Mycobacterium Tuberculosis Infection and Inflammation: what is Beneficial for the Host and for the Bacterium? Front Microbiol. 2011;2:2. doi:10.3389/fmicb.2011.00002.
Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72. doi:10.1016/S0140-6736(10)62173-3.
Smith S, Liggitt D, Jeromsky E, Tan X, Skerrett SJ, Wilson CB. Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun. 2002;70(4):2082–9.
Toossi Z. The inflammatory response in Mycobacterium tuberculosis infection. Arch Immunol Ther Exp. 2000;48(6):513–9.
Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis. 2005;64(Suppl 4):iv24–8. doi:10.1136/ard.2005.042531.
Nezami N, Ghorbanihaghjo A, Rashtchizadeh N, Argani H, Tafrishinejad A, Ghorashi S, et al. Atherogenic changes of low-density lipoprotein susceptibility to oxidation, and antioxidant enzymes in pulmonary tuberculosis. Atherosclerosis. 2011;217(1):268–73. doi:10.1016/j.atherosclerosis.2011.03.025.
Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24(7):1161–70. doi:10.1161/01.ATV.0000133194.94939.42.
Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-kappaB signaling in atherosclerotic calcification. Circ Res. 2011;108(12):1482–93. doi:10.1161/CIRCRESAHA.110.234245.
Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(1):S1. doi:10.1186/ar2165.
Mohammadpour AH, Shamsara J, Nazemi S, Ghadirzadeh S, Shahsavand S, Ramezani M. Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: a pilot study. Thrombosis. 2012;2012:306263. doi:10.1155/2012/306263.
Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12(1):17–25. doi:10.1016/j.molmed.2005.11.007.
Peluso I, Morabito G, Urban L, Ioannone F, Serafi M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets. 2012;12(4):351–60.
Suresh DR, Annam V, Pratibha K, Prasad BV. Total antioxidant capacity–a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci. 2009;16:61. doi:10.1186/1423-0127-16-61.
Suresh DR, Annam V, Krishnappa Pratibha H. Immunological correlation of oxidative stress markers in tuberculosis patients. Int J Biol Med Res. 2010;1(4):185–7.
Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem. 2005;280(17):17497–506. doi:10.1074/jbc.M409332200.
De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012;2012:369432. doi:10.1155/2012/369432.
Andrade Junior DR, Santos SA, Castro I, Andrade DR. Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. Braz J Infect Dis. 2008;12(3):226–33.
Sharma S, Rathored J, Ghosh B, Sharma SK. Genetic polymorphisms in TNF genes and tuberculosis in North Indians. BMC Infect Dis. 2010;10:165. doi:10.1186/1471-2334-10-165.
Fiorenza G, Rateni L, Farroni MA, Bogue C, Dlugovitzky DG. TNF-alpha, TGF-beta and NO relationship in sera from tuberculosis (TB) patients of different severity. Immunol Lett. 2005;98(1):45–8. doi:10.1016/j.imlet.2004.09.008.
Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med. 2009;15(10):468–77. doi:10.1016/j.molmed.2009.08.004.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.
Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med. 2002;347(3):175–84. doi:10.1056/NEJMoa013096.
Morena M, Jaussent I, Halkovich A, Dupuy AM, Bargnoux AS, Chenine L, et al. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS ONE. 2012;7(5):e36175. doi:10.1371/journal.pone.0036175.
Conflict of interest
None declared.
Disclosure
No financial interests related to the material in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghorbanihaghjo, A., Argani, H., Rashtchizadeh, N. et al. The Effect of Tuberculosis on Serum Receptor Activator of Nuclear Factor-k B Ligand, Osteoprotegerin, and Total Antioxidant Capacity. Ind J Clin Biochem 30, 430–434 (2015). https://doi.org/10.1007/s12291-014-0464-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-014-0464-y